Primary Liver Cancer Clinical Trials
2 recruiting trials for Primary Liver Cancer. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Primary Liver Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Nanjing Medical University (1), Wuhan Ammunition Life-tech Co., Ltd (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is plasma GNB4 and Riplet genes methylation detection (diagnostic_test, 1 trial).
Track Primary Liver Cancer trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Recurrent Liver Cancer: Reconceptualization and Reevaluation
The goal of this observational study is to determine if a specific protein can serve as a novel indicator for the recurrence of liver cancer. The study will focus on recurrent...
cfDNA Methylation for Liver Cancer Recurrence Detection
Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Primary Liver Cancer, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Primary Liver Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Primary Liver Cancer, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.